These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28457100)

  • 41. [Graves' ophthalmopathy].
    Hiromatsu Y
    Nihon Rinsho; 2006 May; Suppl 1():307-10. PubMed ID: 16776151
    [No Abstract]   [Full Text] [Related]  

  • 42. Primer on Graves' Disease: What the Ophthalmologist Should Know and Do.
    Kikani N; Gaba R
    Int Ophthalmol Clin; 2021 Apr; 61(2):21-31. PubMed ID: 33743526
    [No Abstract]   [Full Text] [Related]  

  • 43. Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities.
    Molnár I; Szentmiklósi JA; Somogyiné-Vári É
    Exp Clin Endocrinol Diabetes; 2017 Sep; 125(8):514-521. PubMed ID: 28750432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
    Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
    Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Graves' disease: clinical pathophysiology, presentation and treatment options.
    Holt K
    J Pract Nurs; 2010; 60(3):13-8. PubMed ID: 21175104
    [No Abstract]   [Full Text] [Related]  

  • 46. Thyroid eye disease.
    Perros P; Neoh C; Dickinson J
    BMJ; 2009 Mar; 338():b560. PubMed ID: 19270020
    [No Abstract]   [Full Text] [Related]  

  • 47. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Management of Graves' ophthalmopathy by using orbital magnetic resonance imaging].
    Hiromatsu Y; Eguchi H; Tani J
    Nihon Rinsho; 2012 Nov; 70(11):1932-7. PubMed ID: 23214064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The stepwise establishment of standardized treatment for the thyroid eye disease].
    Qian J
    Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):404-407. PubMed ID: 28606260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
    Bartalena L
    J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Graves upper eyelid retraction.
    Cruz AA; Ribeiro SF; Garcia DM; Akaishi PM; Pinto CT
    Surv Ophthalmol; 2013; 58(1):63-76. PubMed ID: 23217588
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
    Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
    Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves' ophthalmopathy.
    Jankauskiene J; Imbrasiene D
    Medicina (Kaunas); 2006; 42(11):900-3. PubMed ID: 17172791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thyroid Orbitopathy.
    Wang Y; Tooley AA; Mehta VJ; Garrity JA; Harrison AR; Mettu P
    Int Ophthalmol Clin; 2018; 58(2):137-179. PubMed ID: 29517649
    [No Abstract]   [Full Text] [Related]  

  • 56. Reconstitution Graves' disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis.
    Tailor IK; Akil M; Rennie I; Ross RJ; Snowden JA
    QJM; 2012 Apr; 105(4):369-71. PubMed ID: 21450898
    [No Abstract]   [Full Text] [Related]  

  • 57. Graves ophthalmopathy: continuing quest in search of initiating factors and new therapies.
    Fatourechi V
    Endocr Pract; 2008; 14(4):412-4. PubMed ID: 18558590
    [No Abstract]   [Full Text] [Related]  

  • 58. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy.
    Campi I; Vannucchi G; Salvi M
    Eur J Endocrinol; 2016 Sep; 175(3):R117-33. PubMed ID: 27032693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Choroidal Thickness in Patients with Graves' Ophthalmopathy.
    Çalışkan S; Acar M; Gürdal C
    Curr Eye Res; 2017 Mar; 42(3):484-490. PubMed ID: 27419847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.